Patents by Inventor Kensuke Nakamura
Kensuke Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12219688Abstract: A dielectric barrier plasma generator includes: a dielectric substrate, a high-voltage electrode provided on a first surface of the dielectric substrate, a low-voltage electrode provided to face a second surface of the dielectric substrate, a power introduction section provided at a first end of the high-voltage electrode, a gas channel formed from a first end to a second end thereof between the dielectric substrate and the low-voltage electrode to allow gas to flow from the first end of the gas channel to the second end thereof, and a blowout outlet formed at the second end of the gas channel to blow out the gas that has flown through the gas channel and plasma that has been generated in the gas channel. The dielectric substrate includes a portion having a thickness being thinner when being closer to the blowout outlet.Type: GrantFiled: January 18, 2021Date of Patent: February 4, 2025Assignee: Ushio Denki Kabushiki KaishaInventors: Takahiro Hiraoka, Kensuke Nakamura, Takanori Samejima
-
Publication number: 20240400681Abstract: Provided are methods for producing a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert human T cell suppression function.Type: ApplicationFiled: July 9, 2024Publication date: December 5, 2024Applicant: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Publication number: 20240381517Abstract: The dielectric barrier discharge plasma generator includes: a dielectric substrate that exhibits a plate shape extending in a first direction and has a first surface and a second surface located on an opposite side of the first surface in a second direction orthogonal to the first direction; a first electrode disposed on the dielectric substrate on a side of the first surface; a second electrode disposed at a position separated from the second surface of the dielectric substrate in the second direction; a gas flow path that is formed by a gap between the dielectric substrate and the second electrode and through which a gas flows in a third direction orthogonal to the first direction and the second direction; and an outlet provided at a first end which is one end portion of the gas flow path in the third direction.Type: ApplicationFiled: February 28, 2022Publication date: November 14, 2024Applicant: Ushio Denki Kabushiki KaishaInventors: Kensuke NAKAMURA, Takahiro HIRAOKA
-
Publication number: 20240299573Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: April 8, 2024Publication date: September 12, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20240294660Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.Type: ApplicationFiled: May 10, 2024Publication date: September 5, 2024Applicants: National University Corporation Kobe University, Daiichi Sankyo Company, LimitedInventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
-
Patent number: 12071478Abstract: Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.Type: GrantFiled: September 7, 2017Date of Patent: August 27, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Patent number: 12024566Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.Type: GrantFiled: July 9, 2019Date of Patent: July 2, 2024Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Takashi Matozaki, Mayumi Sue, Kensuke Nakamura, Chigusa Yoshimura
-
Publication number: 20240182569Abstract: To provide a stable bispecific molecule. A Fab that specifically binds to CD3, the Fab comprising the following CDRH1 to 3 and CDRL1 to 3: CDRH1 consisting of the amino acid sequence represented by SEQ ID NO: 32; CDRH2 consisting of the amino acid sequence represented by SEQ ID NO: 33; CDRH3 consisting of the amino acid sequence represented by SEQ ID NO: 34; CDRL1 consisting of the amino acid sequence represented by SEQ ID NO: 35; CDRL2 consisting of the amino acid sequence represented by SEQ ID NO: 36; and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO: 37.Type: ApplicationFiled: March 28, 2022Publication date: June 6, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makiko NAKAYAMA, Kensuke NAKAMURA, Shinji FURUZONO, Ryota MATSUMOTO
-
Patent number: 11952423Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: GrantFiled: May 16, 2023Date of Patent: April 9, 2024Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
-
Publication number: 20230348616Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.Type: ApplicationFiled: March 29, 2021Publication date: November 2, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230287119Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.Type: ApplicationFiled: April 3, 2023Publication date: September 14, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Tohru TAKAHASHI, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
-
Publication number: 20230287121Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: ApplicationFiled: May 16, 2023Publication date: September 14, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230248819Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.Type: ApplicationFiled: June 10, 2021Publication date: August 10, 2023Inventors: Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI, Ken ISHII, Kouji KOBIYAMA, Eiko NAMBA, Tatsuya OKA, Miyuki TOZUKA, Nao JONAI, Yoshikuni ONODERA, Fumihiko TAKESHITA, Takashi SUZUKI, Takako NIWA, Makoto KOIZUMI, Kensuke NAKAMURA
-
Publication number: 20230226205Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: July 26, 2022Publication date: July 20, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA
-
Publication number: 20230212306Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.Type: ApplicationFiled: December 27, 2022Publication date: July 6, 2023Applicants: Daiichi Sankyo Company, Limited, The University of TokyoInventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
-
Publication number: 20230158452Abstract: A gas treatment method includes: a process (a) of allowing gas to be treated in which a target substance to be treated is mixed with air to pass through inside a housing, the target substance to be treated exhibiting volatility at room temperature and belonging to at least one substance selected from a group consisting of carbon compounds, nitrogen compounds, and sulfur compounds; a process (b) of introducing ozone into a space through which the gas to be treated flows inside the housing at 200° C. or lower; a process (c) of stirring the gas to be treated after the process (b); and a process (d) of heating the gas to be treated to 300° C. or higher after executing the process (c).Type: ApplicationFiled: June 15, 2021Publication date: May 25, 2023Applicant: Ushio Denki Kabushiki KaishaInventors: Yuichi Otsuka, Takahiro Hiraoka, Masaki Miura, Kensuke Nakamura
-
Patent number: 11628223Abstract: A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].Type: GrantFiled: September 28, 2018Date of Patent: April 18, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Patent number: 11618785Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.Type: GrantFiled: December 21, 2017Date of Patent: April 4, 2023Assignee: Daiichi Sankyo Company, LimitedInventors: Tohru Takahashi, Chigusa Yoshimura, Shiho Kozuma, Kensuke Nakamura, Chikako Suzuki, Junya Ichikawa
-
Publication number: 20230100544Abstract: A dielectric barrier plasma generator includes: a dielectric substrate, a high-voltage electrode provided on a first surface of the dielectric substrate, a low-voltage electrode provided to face a second surface of the dielectric substrate, a power introduction section provided at a first end of the high-voltage electrode, a gas channel formed from a first end to a second end thereof between the dielectric substrate and the low-voltage electrode to allow gas to flow from the first end of the gas channel to the second end thereof, and a blowout outlet formed at the second end of the gas channel to blow out the gas that has flown through the gas channel and plasma that has been generated in the gas channel. The dielectric substrate includes a portion having a thickness being thinner when being closer to the blowout outlet.Type: ApplicationFiled: January 18, 2021Publication date: March 30, 2023Applicant: Ushio Denki Kabushiki KaishaInventors: Takahiro Hiraoka, Kensuke Nakamura, Takanori Samejima
-
Publication number: 20230084707Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: April 5, 2022Publication date: March 16, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA